Earnings Call
Apr 22, 2026
Q1 FY2026
EPS Estimate
0.79
EPS Actual
0.80
Post-Earnings Close
$64.87
Earnings Reaction
+9.0%
Boston Scientific's first quarter came in at the high end of expectations, 9.4% organic revenue growth, $5.203 billion in reported revenue, and adjusted EPS of $0.80, but the headline numbers were quickly overshadowed by a meaningful guidance reduction that management acknowledged with unusual candor. The full-year organic growth outlook was cut to 6.5%, 8.0% from a prior range implying roughly 10%, and full-year adjusted EPS guidance was set at $3.34, $3.41, representing 9%, 11% growth. CEO Mike Mahoney was direct: this is not the kind of company that misses its commitments, and the revision reflects three specific and largely unanticipated deteriorations, in WATCHMAN, Electrophysiology, and Urology.
Report generated on Apr 22, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full BSX analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.